Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
Clinical trial NCT03744910 · TERMINATED
Trial details
- NCT number
- NCT03744910
- Sponsor
- CSL Behring
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-14
- Primary completion
- 2024-04-08
- Enrollment
- 194
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.